Canada: Appeal Of Prohibition Order Dismissed (Intellectual Property Weekly Abstracts Bulletin - October 21, 2013)

Last Updated: October 29 2013
Most Read Contributor in Canada, September 2016

Edited by Chantal Saunders and Beverley Moore and Adrian Howard

NOC Proceedings

Appeal of Prohibition Order Dismissed

Teva Canada Limited v. Novartis Pharmaceuticals Canada Inc, 2013 FCA 244
Drug: zoledronic acid

The Federal Court issued an order prohibiting Teva from entering the market with its version of zoledronic acid until the expiration of two patents. Teva appealed the order with respect to one of the patents. (Decision here, summarized here.) The Federal Court of Appeal (FCA) dismissed the appeal.

The appeal related mainly to obviousness issues. The FCA held that the Trial Judge did not apply a higher standard than that set out in Sanofi to determine whether the patent was obvious. Furthermore, the FCA was not convinced that the Trial Judge made an overriding and palpable error in appreciating the evidence.

Evidence Struck and Reply Granted after Partial Reversal

Pfizer Canada Inc. v. Apotex Inc., 2013 FC 1036
Drug: celecoxib

In this case, there was an Order for partial reversal of evidence. Apotex brought a motion to strike substantial portions of the affidavits of three of Pfizer's experts on validity, alleging that they relied on an extensive number of clinical studies and other documents which Apotex argues are facts, and should have been disclosed as part of the "fact" evidence.

The Court held that Directions of the Court carry the weight of judicial decision making and are the expectation of what will happen in the conduct of a case. However, as there was dispute over the meaning of "fact" evidence, the Court held that it could not be definitively said that the Court's Direction was contravened. The Court struck portions of Pfizer's affidavits, criticising Apotex' witnesses for not commenting on certain pieces of art cited by Pfizer's experts. Apotex was granted reply with respect to other issues.

Patent Actions

Patent Infringement, Trade-mark, Copyright and Competition Act Claims Dismissed

Distrimedic Inc. v. Dispill Inc. and Emballages Richards Inc., 2013 FC 1043

In this case, Distrimedic sought a declaration of non-infringement in relation to a kit for the manufacture of a set of individual pill containers. Richards filed a disclaimer, and then a Statement of Defence and Counterclaim, adding a number of new allegations and legal claims, and joining a number of other parties. In particular, allegations relating to copyright infringement, trade-mark rights and breach of the Competition Act were added. The original Claim was discontinued, but the Counterclaim proceeded to this hearing.

The Court construed the patent, and held that Distrimedic did not infringe the patent. The Court refused to definitively rule on whether the disclaimer was valid, however held that there was insufficient evidence to constitute a mistake, accident or inadvertence for the purposes of establishing a valid disclaimer. In addition, the inventor was not consulted. However, the Court held that Distrimedic had failed to show there was anything in the Patent Act that would prevent the patentee from returning the pre-disclaimer patent. The Court accepted the evidence that the patent was neither obvious nor anticipated.

In relation to the non-patent issues, the Court held that the allegations of misrepresentation had not been made out, as the evidence was not sufficient to establish, on a high preponderance of probabilities, that Distrimedic made misleading representations with respect to Richards' wares. The Court also held that Richards had failed to show it holds trade-mark rights in the colour scheme, because it has a purely functional purpose, there was no intention to use it as a trade-mark, and there was no trade-mark recognition among the relevant public. The Court then held that the Label Form could not be protected by copyright under the Copyright Act. Thus, the counterclaim was dismissed as a whole.

Trade-Mark Decisions

LAZARO COHIBA for rum is confusing with COHIBA-brand tobacco

Empresa Cubana Del Tabaco et al. v. Tequila Cuervo, S.A. Dec. V. 2013 FC 1010

Tequila Cuervo sought a trade-mark for LAZARO COHIBA based on proposed use in Canada with rum. Empresa Cubana Del Tabaco opposed by arguing, among other things, it would be confused with its COHIBA registered trade-marks used in conjunction with tobacco products. The Trade-marks Opposition Board rejected the opposition. The Federal Court overturned that decision on appeal based on new evidence filed. Finding COHIBA is a widely known brand across Canada, and recognizing the relationship between smoking and alcohol, it was found that a consumer would likely think that the rum was from the same source as the tobacco.

ZENERGY confusing with ENERGIE for the hurried consumer

International Stars S.A. v. Simon Chang Design Inc., 2013 FC 1041

Simon Chang applied for registration of the trade-mark ZENERGY BY/POUR SIMON CHANG & Design (the Mark) in association with certain sports clothing. International Stars unsuccessfully opposed the registration on the basis of evidence that it had used the trade-mark ENERGIE for similar wares. On appeal, the Federal Court reversed the earlier decision, finding that the Registrar performed a side-by-side comparison and not one of first impression in the mind of a casual consumer. The Court found that casual consumer would be confused and therefore directed the Registrar to refuse the application.

Neither party entitled to register HORTILUX

Hortilux Schreder B.V. v. Iwasaki Electric Co., 2013 FC 1034

Both parties to this proceeding are seeking to register the mark HORTILUX in association with lighting equipment used in the horticultural industry, and each party opposes the other's efforts. Hortilux Shréder was unsuccessful before the Trade-marks Board, and appealed to the Federal Court, the subject of the present decision. In reviewing the decision, the Court decided that the Board had relied upon the correct legal principles and did not misapprehend the evidence. The new evidence filed on appeal was found to not have materially affected the Board's conclusions, and therefore the appeal was dismissed.

Previously, Iwasaki had successfully registered the mark, but that was overturned by the Federal Court, and upheld on appeal. So far, neither party has registered rights to the mark.

FRENCH PRESS is a generic term

Bodum USA Inc. v. Meyer Housewares Canada Inc., 2013 FCA 240

Bodum previously sued Meyer for infringement, passing off and depreciation of goodwill of their mark FRENCH PRESS. (Decision here, summarized here.) Bodum lost that decision and appealed, but the Court dismissed from the bench. The case turned on the issue of distinctiveness, but the panel failed to find any error in law or fact warranting intervention. FRENCH PRESS was considered to be a common name for the non-electric coffee making device at issue, and its use was a bona fide commercial use as a generic term.

Other Decisions of Interest

ss. 53(2) of the Patent Act is a shield, not a sword

F. Hoffmann-La Roche AG v. The Commissioner of Patents, 2013 FC 1001

Hoffmann-La Roche was denied the opportunity to correct a single word error in a patent's disclosure pursuant to ss.53(2) of the Patent Act. The impetus for the application arose from an earlier Federal Court decision where the Court admonished a patentee for not correcting a patent as drafted. However, that statement was found to have limited value, if any, as a precedent.

Nonetheless, in this era of the "promise of the patent", the patentee sought to remedy the uncertainty the single abbreviation "viz" could create when reading the disclosure. The Court determined that ss. 53(2) could not be a stand alone provision, rather it can only be invoked as a defence to a claim under ss.53(1). Allowing an amendment to a patent under judicial supervision is a policy choice best left for Parliament to make.

Other News

Although the details have not been made official, it has been reported that the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) would result in Canada introducing a form of patent term restoration, for up to two years, for pharmaceutical patents. Additional changes for pharmaceutical patents may also be forthcoming; however, the text of the treaty was only agreed to in principle and is not yet publicly available.

Bill C-434, the "Terminator Seeds Ban Act", is reinstated in Parliament

A private-members bill, C-434, has been reinstated in Parliament. The bill is entitled the "Terminator Seeds Ban Act", and it would make it an offence to release terminator seeds. It would also amend the Patent Act, making the technology ineligible for patent protection. Private member bills rarely become law.

Health Canada has issued a Post-Notice of Compliance (NOC) Changes: Quality Document.

The PMPRB has released its 2012 Annual Report.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.